Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of ...

The castration-sensitive prostate cancer market presents opportunities driven by rising prostate cancer incidences, an aging population, growing awareness, and improved early diagnosis. Successive ...

Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...

Bayer (BAYRY) is running an Australian study called “Treatment Patterns and Characteristics of Patients Receiving Androgen Receptor Pathway Inhibitors in a Real-world Setting in Australia: A ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...

Please provide your email address to receive an email when new articles are posted on . FDA granted approval to darolutamide for metastatic hormone-sensitive prostate cancer. Randomized phase 3 trial ...

Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...